<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>85</patient-age><report-id>CA-CELGENEUS-028-21880-13013465</report-id><gender>female</gender><reactions><reaction>DECEASED</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REVLIMID</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10028228</indication></indications><outcomes><outcome>Death</outcome></outcomes><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289221</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102653</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-CELGENEUS-028-21880-13013465</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-22</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-22</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-CELGENEUS-028-21880-13013465</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reportergivename>Ghislain</reportergivename>
      <reporterfamilyname>Cournoyer</reporterfamilyname>
      <reporterstreet>145 Avenue de la Providence</reporterstreet>
      <reportercity>Lachute</reportercity>
      <reporterstate>QC</reporterstate>
      <reportercountry>CA</reportercountry>
      <qualification code="1">Physician</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>M-B</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19270819</patientbirthdate>
      <patientsex code="2">Female</patientsex>
      <patientmedicalhistorytext lang="en">None Provided</patientmedicalhistorytext>
      <patientdeath>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">DECEASED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionoutcome code="5">fatal</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>CA</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform normalized="capsule">Capsules</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>2012-10-12</drugstartdate>
        <actiondrug code="6">Not Applicable</actiondrug>
        <drugrecurreadministration code="3">Unknown</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical><Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">DECEASED</Semaphore>(CANADA) <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>information was received on 22Jan2013 via a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>from the prescriber's office regarding an <Semaphore x="1387834" class="Patient Age" value="85" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="85" score="1.00" ID="">85 </Semaphore>year old </Semaphore>female patient who received <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.87" ID="256603">Revlimid</Semaphore>. This patient received <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.87" ID="256603">Revlimid </Semaphore><Semaphore x="4859317408759809" class="Medicine - Revlimid - Dose" value="10mg" score="0.49" ID="">10mg </Semaphore><Semaphore x="4859377538301953" class="Medicine - Revlimid - Frequency" value="PO" score="0.49" ID="">PO </Semaphore>from 12Oct2012 for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">multiple myeloma</Semaphore>. Lot number and expiration date were not provided. Relevant medical history and concomitant medications were not included. Per a <Semaphore x="1919392" class="Disease or Finding" value="Factitious Disorder" score="1.00" ID="C92198">fax </Semaphore>from the prescriber's office, the patient was <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">deceased</Semaphore>. The date and <Semaphore x="1728496" class="Disease or Finding" value="Cause of Death" score="1.00" ID="C81239">cause of <Semaphore x="2895537" class="MedDRA LLT" value="Death" score="1.00" ID="10011906">death </Semaphore></Semaphore>were <Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">not specified</Semaphore>. The reporter did not assess the causal relationship of the <Semaphore x="1837270" class="Disease or Finding" value="Death" score="1.00" ID="C28554">death </Semaphore>to <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.87" ID="256603">Revlimid</Semaphore>. Additional information cannot be requested from the prescriber as consent was not granted.</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and DECEASED suggests that a causal relationship is possible, but underlying multiple myeloma could provide an alternative explanation. Additional information regarding the patient's disease status prior to death, relevant medical history, concurrent illnesses, concomitant medications, details about the death and therapy details are necessary to assist in providing a more complete causality assessment; however, consent was not granted to request additional information from the prescriber.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>